This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.
Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug
by Zacks Equity Research
Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $108.24, moving +0.4% from the previous trading session.
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
by Zacks Equity Research
Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $107.81, moving -1.11% from the previous trading session.
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
by Zacks Equity Research
The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
by Zacks Equity Research
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
by Zacks Equity Research
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NULV
Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe
by Kinjel Shah
The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.
Pharma Stock Roundup: J&J to End Hypertension Study & Other Regulatory Updates
by Kinjel Shah
J&J (JNJ) to end a late-stage study on macitentan for CTEPH. Merck's (MRK) Ebola vaccine gets approval in Europe for use in kids.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $107.94, marking a +1.36% move from the previous day.
Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $109.84, marking a +0.79% move from the previous day.
Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates
by Kinjel Shah
J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.
Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal
by Zacks Equity Research
Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.
Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
by Zacks Equity Research
Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
by Zacks Equity Research
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
10 Drugs Selected for Medicare Price Reduction
by Zacks Equity Research
10 Drugs Selected for Medicare Price Reduction
Medicare Drugs Targeted Under Inflation Reduction Act
by Mark Vickery
Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
by Zacks Equity Research
Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.
Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.